Aktis Oncology, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
AKTS$17.45+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue: | ||
| Collaboration revenue | $3,227 | $1,447 |
| Operating expenses: | ||
| Research and development | 20,036 | 15,863 |
| General and administrative | 5,897 | 3,727 |
| Total operating expenses | 25,933 | 19,590 |
| Loss from operations | (22,706) | (18,143) |
| Other income (expense): | ||
| Interest income | 4,384 | 3,171 |
| Other expense, net | (3) | (13) |
| Total other income, net | 4,381 | 3,158 |
| Net loss | $(18,325) | $(14,985) |
| Net loss per share - basic and diluted | $(0.38) | $(18.60) |
| Weighted-average common stock outstanding, basic and diluted | 48,630,038 | 805,821 |
| Comprehensive loss: | ||
| Net loss | $(18,325) | $(14,985) |
| Other comprehensive loss: | ||
| Net unrealized loss on marketable securities held | (283) | (58) |
| Comprehensive loss | $(18,608) | $(15,043) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.